A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-R)

I1F-MC-RHCR -

The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Plaque Psoriasis
What the trial is testing?
Guselkumab, Ixekizumab
Could I receive a Placebo?
Yes
Enrollment Goal
1027
Trial Dates
Nov 9, 2018 - Jan 8, 2020
How long will I be in the trial?
The study will last about 24 weeks and may include up to 12 visits (follow up includes up to 3 visits).
Trial Phase
IV

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.